Application of low dose of FK506 in pancreas transplantation model in Wistar-SD rats

References

• Vu, M.D., Qi, S., Xu, D., Wu, J., Fitzsimmons, W.E., Sehgal, S.N., Dumont, L., Busque, S., Daloze, P., Chen, H. Tacrolimus (Fk506) and sirolimus (Rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997, 64:1853–1856.
   Google Scholar
• Antignac, M., Barrou, B., Farinotti, R., Lechat, P., Urien, S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 2007, 64:750–757.
   PubMed Web of Science ®Google Scholar
• Blanchet, B., Duvoux, C., Costentin, C.E., Barrault, C., Ghaleh, B., Salvat, A., Jouault, H., Astier, A., Tod, M., Hulin, A. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. Ther Drug Monit 2008, 30:412–418.
   PubMedGoogle Scholar
• Patel, J.K., Kobashigawa, J.A. Tacrolimus in heart transplant recipients: an overview. BioDrugs 2007, 21:139–143.
   PubMedGoogle Scholar
• Hachem, R.R., Yusen, R.D., Chakinala, M.M., Meyers, B.F., Lynch, J.P., Aloush, A.A., Patterson, G.A., Trulock, E.P. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 2007, 26:1012–1018.
   PubMed Web of Science ®Google Scholar
• Rossetti, M., Piccoli, G.B., Burdese, M., Guarena, C., Giraudi, R., Mezza, E., Consiglio, V., Soragna, G., Messina, M., Segoloni, G.P. Tailored immunosuppression and steroid withdrawal in pancreas-kidney transplantation. Rev Diabet Stud 2004, 1:129–136.
   PubMedGoogle Scholar
• Mazali, F.C., Lalli, C.A., Alves-Filho, G., Mazzali, M. Posttransplant diabetes mellitus: incidence and risk factors. Transplant Proc 2008, 40:764–766.
   PubMedGoogle Scholar
• Sharma, A., Minz, M., Singh, S. Incidence of glucose metabolic abnormalities in Indian living renal allograft recipients on tacrolimus-based triple drug immunosuppression. Transplant Proc 2008, 40:2414–2415.
   PubMedGoogle Scholar
• Saudek, F., Malaise, J., Boucek, P., Adamec, M. Euro-SPK Study Group. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol Dial Transplant 2005, 20 Suppl 2:3–10.
   Google Scholar
• Barone, G.W., Ketel, B.L., Abul-Ezz, S.R., Lightfoot, M.L. Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation. JOP 2002, 3:49–53.
   PubMedGoogle Scholar
• Li, Q.Y., Li, F., Sun, J.H., Chi, Y.Y., Yin, H.S., Liu, S.Q., Mei, Y.H. Mechanisms of diabetes mellitus induced with FK506 in SD rats models. Immunopharmacol Immunotoxicol 2009, 31:675–681.
   PubMed Web of Science ®Google Scholar
• Uchizono, Y., Iwase, M., Nakamura, U., Sasaki, N., Goto, D., Iida, M. Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling. Endocrinology 2004, 145:2264–2272.
   PubMed Web of Science ®Google Scholar
• Wu, K.K., Huan, Y. Streptozotocin-induced diabetic models in mice and rats. Current Protocols Pharmacol 2008. Doi: 10.1002/0471141755.ph0547s40.
   Google Scholar
• Kohda, Y., Shirakawa, H., Yamane, K., Otsuka, K., Kono, T., Terasaki, F., Tanaka, T. Prevention of incipient diabetic cardiomyopathy by high-dose thiamine. J Toxicol Sci 2008, 33:459–472.
   PubMedGoogle Scholar
• Mood, Z.A., Mehrabi, A., Schmied, B.M., et al. Review of various techniques of pancreas transplantation in rat model journal of surgical research. J Surg Res 2008, 145:205–213.
   PubMedGoogle Scholar
• Shimizu, T., Ishida, H., Shirakawa, H., Omoto, K., Tanabe, K., Yamaguchi, Y. Clinical and histological analysis of chronic tacrolimus nephrotoxicity in renal allografts. Transplant Proc 2008, 40:2370–2372.
   PubMedGoogle Scholar
• Zhou, X., Yang, G., Davis, C.A., Doi, S.Q., Hirszel, P., Wingo, C.S., and Agarwal, A. Hydrogen peroxide mediates FK506-induced cytotoxicity in renal cells. Kidney International 2004, 65:139–147.
   PubMed Web of Science ®Google Scholar
• Morgan, C., Sis, B., Pinsk, M., Yiu, V. Renal interstitial fibrosis in children treated with FK506 for nephrotic syndrome Nephrol Dial Transplant 2011, 26:2860–2865.
   Google Scholar
• Li, J., Ma, L., Zhao, L., Zhang, S., Hou, X., Wang, G., Luo, K. Fk506 caused 2 cases liver damage after kidney transplantation and review of literature[J].Clinical Med 2007, 27:5–7.
   Google Scholar
• Saboo, D., Shah, P.R., Goplani, K.R., Feroz, A., Gumber, M., Vanikar, A.V., Trivedi, H.L. Posttransplant diabetes mellitus: a single-center study. Transplant Proc 2008, 40:1111–1113.
   PubMedGoogle Scholar
• DiMartini, A.F., Trzepacz, P.T., Pajer, K.A., Faett, D., Fung, J. Neuropsychiatric side effects of FK506 vs. cyclosporine A. First-week postoperative findings. Psychosomatics 1997, 38:565–569.
   PubMedGoogle Scholar
• Cox, K.L., Lawrence-Miyasaki, L.S., Garcia-Kennedy, R., Lennette, E.T., Martinez, O.M., Krams, S.M., Berquist, W.E., So, S.K., Esquivel, C.O. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995, 59:524–529.
   PubMed Web of Science ®Google Scholar
• Li, F., Li, Q. Effects of different dose of FK506 on endocrine function of pancreatic islets and damage of β cells of pancreatic islets in a Wistar rat model. Immunopharmacol Immunotoxicol 2010, 32:333–338.
   PubMed Web of Science ®Google Scholar